ING Groep NV Makes New $8.87 Million Investment in Jazz Pharmaceuticals PLC $JAZZ

ING Groep NV acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 52,200 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,874,000.

Other institutional investors have also recently bought and sold shares of the company. Hilltop National Bank acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth $36,000. LRI Investments LLC acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth $38,000. Danske Bank A S acquired a new position in Jazz Pharmaceuticals during the third quarter worth $40,000. Geneos Wealth Management Inc. raised its holdings in Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Jazz Pharmaceuticals by 1,383.3% in the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 332 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $238.57 on Monday. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $243.32. The company has a 50-day simple moving average of $213.11 and a 200 day simple moving average of $187.01. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The company has a market capitalization of $14.97 billion, a PE ratio of -11,922.54, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The business had revenue of $1.07 billion during the quarter. On average, research analysts predict that Jazz Pharmaceuticals PLC will post 21.59 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Truist Financial upgraded shares of Jazz Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. TD Cowen increased their target price on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Sanford C. Bernstein assumed coverage on shares of Jazz Pharmaceuticals in a report on Thursday, May 21st. They issued a “market perform” rating and a $229.00 target price for the company. Wells Fargo & Company increased their target price on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings upgraded shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $242.65.

Insider Buying and Selling

In related news, Director Heather Ann Mcsharry sold 2,000 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the sale, the director owned 18,449 shares in the company, valued at approximately $4,446,209. This trade represents a 9.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the sale, the director owned 384,682 shares of the company’s stock, valued at $73,281,921. This trade represents a 1.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 10,741 shares of company stock worth $2,287,143. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.